Impact Biomedical (IBO) Times Interest Earned (2022 - 2026)
Impact Biomedical's (IBO) quarterly Times Interest Earned came in at 10.48 in Q2 2026, down 136.27% on a YoY basis from 28.89 in Q2 2025, and up 69.33% quarter-over-quarter from 34.16 in Q1 2026.
Powered by 
Analysis
Impact Biomedical (IBO) Times Interest Earned (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has reported Times Interest Earned for 5 consecutive years, with 10.48 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Times Interest Earned fell 136.27% year-over-year to 10.48; the trailing twelve-month figure through Jun 2026 stood at 7.76 (up 70.92% YoY), and the FY2024 full-year result was 27.0, down 197.6% from the prior year.
- Times Interest Earned rose to 10.48 in Q2 2026 per IBO's latest filing, from 34.16 in the prior quarter.
- Across five years, Times Interest Earned topped out at 2.4 in Q2 2024 and bottomed at 97.15 in Q4 2024.
- Historically, Times Interest Earned has averaged 14.05 across 5 years, with a median of 8.32 in 2023.
- The widest YoY moves for Times Interest Earned: up 72.4% in 2024, down 966.2% in 2024.
- Over 5 years, Times Interest Earned stood at 10.42 in 2022, then increased by 12.59% to 9.11 in 2023, then slumped by 966.2% to 97.15 in 2024, then soared by 96.28% to 3.62 in 2025, then slumped by 189.57% to 10.48 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered 10.48, 34.16, and 3.62 for Q2 2026, Q1 2026, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 | -10.48 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.48 |
| Mar 31, 2026 | -34.16 |
| Sep 30, 2025 | -3.62 |
| Jun 30, 2025 | -4.43 |
| Mar 31, 2025 | -3.73 |
| Dec 31, 2024 | -97.15 |
| Sep 30, 2024 | -3.70 |
| Jun 30, 2024 | -2.40 |
| Mar 31, 2024 | -3.35 |
| Dec 31, 2023 | -9.11 |
| Sep 30, 2023 | -10.57 |
| Jun 30, 2023 | -8.69 |
| Mar 31, 2023 | -7.95 |
| Dec 31, 2022 | -10.42 |
| Sep 30, 2022 | -9.66 |
| Jun 30, 2022 | -5.40 |